Cantor Fitzgerald Has Weak Forecast for STOK FY2025 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities researchers at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for Stoke Therapeutics in a report released on Thursday, June 12th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will earn ($0.34) per share for the year, down from their previous estimate of $0.03. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Cantor Fitzgerald also issued estimates for Stoke Therapeutics’ FY2026 earnings at ($3.36) EPS.

STOK has been the topic of a number of other research reports. Needham & Company LLC reissued a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday, April 9th. HC Wainwright lowered their target price on Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating on the stock in a research note on Wednesday, May 14th. Finally, Chardan Capital restated a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $23.20.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK opened at $11.66 on Monday. Stoke Therapeutics has a one year low of $5.35 and a one year high of $16.15. The stock has a market capitalization of $636.64 million, a price-to-earnings ratio of 14.76 and a beta of 1.09. The company has a 50-day simple moving average of $9.52 and a 200-day simple moving average of $9.64.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a net margin of 26.33% and a return on equity of 19.08%. The firm had revenue of $22.61 million during the quarter, compared to analysts’ expectations of $4.20 million.

Insider Buying and Selling

In related news, insider Barry Ticho sold 6,471 shares of the company’s stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $10.03, for a total transaction of $64,904.13. Following the transaction, the insider now owns 25,782 shares of the company’s stock, valued at $258,593.46. This represents a 20.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 9.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Rhumbline Advisers grew its stake in shares of Stoke Therapeutics by 6.0% during the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock worth $545,000 after purchasing an additional 2,787 shares during the period. Bank of New York Mellon Corp boosted its holdings in Stoke Therapeutics by 1.4% during the fourth quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company’s stock worth $1,028,000 after buying an additional 1,330 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Stoke Therapeutics by 8.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 342,129 shares of the company’s stock worth $3,774,000 after buying an additional 25,995 shares during the period. Swiss National Bank increased its holdings in Stoke Therapeutics by 20.4% in the fourth quarter. Swiss National Bank now owns 67,300 shares of the company’s stock valued at $742,000 after buying an additional 11,400 shares in the last quarter. Finally, Teacher Retirement System of Texas purchased a new position in Stoke Therapeutics in the fourth quarter valued at about $113,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.